Five Prime Announces Bemarituzumab Plus Chemotherapy Demonstrates Significant Progression-Free and Overall Survival Benefit Compared to Placebo Plus Chemotherapy in Front-Line Advanced Gastric and Gastroesophageal Junction Cancer

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Five Prime Announces Bemarituzumab Plus Chemo Demonstrates Significant PFS and OS Benefit Compared to Placebo Plus Chemo in Front-line Gastric Cancer

Click to view original post